Related Experiment Videos
Chromosome abnormalities in low-grade central nervous system tumors
C A Griffin1, P P Long, B S Carson
1Johns Hopkins Oncology Center, Baltimore, MD 21205.
Cancer Genetics and Cytogenetics
|May 1, 1992
Summary
Most low-grade central nervous system (CNS) tumors exhibit normal karyotypes, differing significantly from high-grade gliomas. Cytogenetic analysis revealed minimal deviations from normal in these slow-growing brain tumors.
Area of Science:
- Neuro-oncology
- Cytogenetics
- Central Nervous System (CNS) Tumors
Background:
- Low-grade CNS tumors like ependymomas, oligodendrogliomas, and astrocytomas affect both children and adults.
- Craniopharyngiomas and choroid plexus papillomas predominantly occur in pediatric populations.
- Understanding the cytogenetic profiles of these tumors is crucial for diagnosis and treatment.
Purpose of the Study:
- To investigate the karyotypic abnormalities in a cohort of 32 low-grade CNS tumors.
- To compare the cytogenetic findings of low-grade CNS tumors with those of high-grade gliomas.
- To identify specific chromosomal alterations associated with different types of low-grade CNS tumors.
Main Methods:
- Karyotype analysis was performed on 32 low-grade CNS tumors.
- Tumor types included oligodendrogliomas, ependymomas, low-grade astrocytomas, craniopharyngiomas, and choroid plexus papillomas.
- Tumor karyotypes were analyzed for deviations from normal stemlines and the presence of sidelines.
Main Results:
- Most oligodendrogliomas (6/10) showed normal karyotypes.
- Ependymomas frequently exhibited abnormalities such as +7, -21, -22, and del(9)(p22).
- Low-grade astrocytomas and other analyzed tumors generally displayed normal karyotypes or minor deviations, contrasting with high-grade gliomas.
Conclusions:
- Low-grade CNS tumors typically show limited chromosomal aberrations compared to high-grade gliomas.
- Specific abnormalities like +7 and del(9p) are more characteristic of high-grade gliomas.
- Cytogenetic analysis highlights distinct differences in the genomic landscape between low-grade and high-grade CNS tumors.